Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the
developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection.
HPV+OPSCC is considered a distinct disease entity, affecting younger patients and has a good
prognosis following treatment. Subsequently, patients can live with the considerable side
effects for several decades.
Radiotherapy and cetuximab (Epidermal Growth Factor Receptor-inhibitor) have demonstrated
similar efficacy to 'platin' chemoradiotherapy (current standard treatment containing
platinum-based compounds) in head and neck cancer, but is potentially less toxic.
Results of this trial will be used to determine the optimum treatment of this debilitating
cancer, with the primary aim of decreasing toxicity and improving quality of life for
HPV+OPSCC patients.
Phase:
Phase 3
Details
Lead Sponsor:
University of Warwick
Collaborators:
Cancer Research UK University of Birmingham University of Oxford